Peter Kaiser Sells 2,974 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) Stock

Ocular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report) insider Peter Kaiser sold 2,974 shares of the stock in a transaction on Friday, May 23rd. The shares were sold at an average price of $7.17, for a total transaction of $21,323.58. Following the transaction, the insider now directly owns 207,104 shares in the company, valued at approximately $1,484,935.68. The trade was a 1.42% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Ocular Therapeutix Price Performance

OCUL traded down $0.13 during trading on Friday, reaching $8.01. The company's stock had a trading volume of 2,177,691 shares, compared to its average volume of 1,411,178. The company has a market cap of $1.28 billion, a price-to-earnings ratio of -6.07 and a beta of 1.51. The firm has a fifty day simple moving average of $7.36 and a two-hundred day simple moving average of $7.95. Ocular Therapeutix, Inc. has a 1 year low of $4.79 and a 1 year high of $11.78. The company has a quick ratio of 12.94, a current ratio of 13.01 and a debt-to-equity ratio of 0.19.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last posted its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.05). The company had revenue of $17.08 million during the quarter, compared to analyst estimates of $16.89 million. Ocular Therapeutix had a negative net margin of 283.74% and a negative return on equity of 45.18%. As a group, analysts anticipate that Ocular Therapeutix, Inc. will post -0.98 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on OCUL. William Blair initiated coverage on shares of Ocular Therapeutix in a research report on Tuesday, April 8th. They set an "outperform" rating for the company. JMP Securities set a $19.00 price objective on Ocular Therapeutix in a research note on Tuesday, March 4th. HC Wainwright reissued a "buy" rating and set a $15.00 target price on shares of Ocular Therapeutix in a report on Thursday. Needham & Company LLC lowered their price target on Ocular Therapeutix from $15.00 to $14.00 and set a "buy" rating on the stock in a research note on Tuesday, May 6th. Finally, Royal Bank of Canada initiated coverage on Ocular Therapeutix in a research report on Tuesday, March 18th. They set an "outperform" rating and a $17.00 price target for the company. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, Ocular Therapeutix currently has a consensus rating of "Moderate Buy" and an average target price of $16.25.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Raymond James Financial Inc. purchased a new stake in Ocular Therapeutix in the fourth quarter valued at $1,722,000. Charles Schwab Investment Management Inc. increased its position in shares of Ocular Therapeutix by 1.9% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,131,485 shares of the biopharmaceutical company's stock worth $9,663,000 after purchasing an additional 21,025 shares during the last quarter. Barclays PLC increased its position in shares of Ocular Therapeutix by 37.1% during the 3rd quarter. Barclays PLC now owns 511,522 shares of the biopharmaceutical company's stock worth $4,451,000 after purchasing an additional 138,441 shares during the last quarter. ProShare Advisors LLC raised its holdings in Ocular Therapeutix by 32.8% in the 4th quarter. ProShare Advisors LLC now owns 51,270 shares of the biopharmaceutical company's stock valued at $438,000 after buying an additional 12,669 shares during the period. Finally, Tower Research Capital LLC TRC lifted its position in Ocular Therapeutix by 2,045.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 8,859 shares of the biopharmaceutical company's stock valued at $76,000 after buying an additional 8,446 shares during the last quarter. 59.21% of the stock is currently owned by hedge funds and other institutional investors.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.